Board of Directors
ABOUT US
Jay Kranzler, MD, PhD
Chairman and Chief Executive Officer
- 24 years as CEO of 2 public companies (with 2 rheumatology product approvals), and most recently led Pfizer’s External R&D Innovation group and R&D Innovate venture fund
- Founding member of McKinsey & Company’s Pharmaceutical Practice
- Professor at NYU Medical & Business schools
- Founder, Board Member, and Advisor to an extensive number of companies and institutions
- Received his MD and PhD (pharmacology) from Yale University.
Paul Brooke
Co-Chairman
- Chairman Emeritus of the Board of Caelum Biosciences, acquired by AstraZeneca in Oct 2021
- Founder and former Managing Partner of venBio, a life sciences venture capital fund
- Former global head of healthcare research and strategy at Morgan Stanley
Lindsay Rosenwald, MD
Director
- Currently also Chairman, President, and CEO at Fortress Biotech (NASDAQ: FBIO)
- Previously Founder/Board Member of multiple biotech companies: Cougar Biotechnology (acquired by JNJ), Chelsea Therapeutics (acquired by Lundbeck), Indevus Pharma (acquired by Endo), Biocryst, Keryx, CorMedix, Ziopharm
Vibeke Strand, MD
Director
- Renowned rheumatologist, consultant and advisor for three decades to companies, FDA, and professional societies in the field
- Participated in 30+ rheumatology drug approvals
- Academic appointments at UCSF and Stanford, each for 10+ years with ~500 publications in the field